Expertise in the Inhibition of Glycemic Peaks Sprint

Due: May 6, 2026

Mondelez, a global leader in snacks, seeks long-term collaboration with US experts having knowledge natural compounds to inhibit glycemic peaks. The goal is to identify and test candidate ingredients allowing the modulation of glycemic response for possible evaluation in finished goods.

Contact us with questions at challenges@techconnect.org

Background

Snack foods often contain glycemic carbohydrates, leading to a glycemic spike upon consumption. To combat this, Mondelez is exploring molecules and ingredients that can reduce that spike without negatively affecting consumer experience.

Mondelez researchers intend to establish a multi-year research collaboration toidentify potential molecules or ingredients of interest for subsequent in vitro evaluation evaluating their effect on digestive enzymes including a-amylase and amyloglucosidase. Ideally, respondents will also be able to assist with clinical trials of finished goods that incorporate most relevant compounds.

Collaboration partners of interest will have:

  • Knowledge of possible compounds exhibiting inhibition of glycemic spikes
    • Only natural compounds are of interest; synthetic inhibition is out of scope
    • Primary focus is on inhibition of alpha-amylase and amyloglucosidase; inhibition of other digestive enzymes is beneficial but not required
  • In vitro testing capabilities that mirror healthy Human adults
    • Non-human in vitro models are potentially of interest if sufficient parallels to humans can be demonstrated

Mondelez is primarily interested in collaborating with academic researchers, however SMEs from commercial entities are potentially of interest. All respondents must be US-based individuals working for a US organization.

Responses proposing specific compounds for consideration are not in scope.

Requirements

TechConnect encourages experts submitting an entry to highlight capabilities in their submission that meet criteria including:

  • Knowledge of natural compounds that inhibit alpha-amylase and amyloglucosidase spikes
  • In vitro carbohydrate digestion testing capabilities
  • Experience collaborating with the food industry
  • Potentially with experience with clinical trials
  • Relevant publications

Business Opportunity for Solvers

Respondents with well-matched capabilities may be contacted directly by TechConnect and/or Mondelez to discuss potential partnership opportunities, including demonstrations, consulting, contract research, licensing, and more. TechConnect may invite top-rated to register or participate in an upcoming event or program.

Response Process

We encourage interested individuals and organizations to submit a brief, high-level, non-confidential response via the online form below.

2026 Expertise in Inhibition of Glycemic Peaks Sprint

Respondent Information

Address
Address
City
State/Province
Zip/Postal
Country

Organization Information

Organization Type
Number of Employees
0 of 250 max words
0 of 150 max words
0 of 250 max words
0 of 150 max words
0 of 150 max words
0 of 200 max words

Maximum file size: 134.22MB